# A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

> **NCT05400369** · PHASE4 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 140 (actual)

## Conditions studied

- COPD Exacerbation Acute

## Interventions

- **DRUG:** Sitafloxacin
- **DRUG:** Moxifloxacin Hydrochloride

## Key facts

- **NCT ID:** NCT05400369
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-10
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05400369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05400369, "A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05400369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*